Inhibition of V-ATPase and Carbonic Anhydrases as Interference Strategy with Tumor Acidification Processes

Current Pharmaceutical Design

Volumn 18, Issue 10, 2012, Pages 1407-1413

  Perez Sayans, Mario ^b   Garcia Garcia, Abel ^b   Scozzafava, Andrea ^a   Supuran, Claudiu T ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Santiago University Clinical Hospital   (Spain)

Author keywords

Anticancer drug; Carvonic anhydrase; Coumarin; Omeprazole; Proton pump inhibitor; Sulfonamide; Tumor pH; V ATP ase

Indexed keywords

6 (HYDROXY 3 METHYLBUTYL) 7 METHOXY 2H CHROMEN 2 ONE; ADENOSINE TRIPHOSPHATASE; ALPHA INTERFERON; BAFILOMYCIN; CARBONATE DEHYDRATASE IX; CARBONATE DEHYDRATASE XII; CONCANAMYCIN A; COUMARIN; GIRENTUXIMAB; GLYCOPROTEIN P; INTERLEUKIN 2; LANSOPRAZOLE; MONOCLONAL ANTIBODY; OMEPRAZOLE; PANTOPRAZOLE; PLANT EXTRACT; PROTON PUMP INHIBITOR; RABEPRAZOLE; UNCLASSIFIED DRUG; V ATPASE;

ADENOCARCINOMA; ADJUVANT THERAPY; ARTICLE; CARCINOGENESIS; CRYSTAL STRUCTURE; ENZYME INHIBITION; HUMAN; KIDNEY CARCINOMA; LYMPHOMA; MEDICAL PROCEDURES; MELANOMA; MULTIDRUG RESISTANCE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR ACIDIFICATION;

EID: 84857757426     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799504876     Document Type: Article

References (85)

1. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nature Rev. Cancer 2004; 4: 891-9.
2. Ebbesen P, Pettersen EO, Gorr TA, et al. Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies. J Enzyme Inhib Med Chem 2009; 24 (S1): 1-39
3. Neri D, Supuran CT. Interfering with pH regulation in tumors as a therapeutic strategy. Nat Rev Drug Discov 2011; 10, 767-77.
4. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008; 7: 168-81.
5. Pastorekova S, Parkkila S, Pastorek J, Supuran CT. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem 2004; 19: 199-229
6. Supuran CT. Carbonic anhydrase inhibitors Bioorg Med Chem Lett 2010; 20: 3467-3474.
7. Nelson N, Harvey WR. Vacuolar and Plasma Membrane ProtonAdenosinetriphosphatases. Physiol Rev 1999;79: 361-385.
8. Martínez-Zaguilán R, Raghunand N, Lynch RM, et al. pH and drug resistance. I. functional expression of plasmalemmal V-type H+-ATPase in drug-resistant human breast carcinoma cell lines. Biochemical Pharmacology, 1999; 57: 1037-46.
9. Johnson DE, Casey JR. Bicarbonate transport metabolons. In Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications, Supuran CT, Winum JY, Eds., Wiley, Hoboken, 2009, pp. 415-37.
10. Sterling D, Brown NJD, Supuran CT, Casey JR. The functional and physical relationship between the DRA bicarbonate transporter and carbonic anhydrase II. Am J Physiol Cell Physiol 2002; 283; C1522-9.
11. + exchanger-dependent intracellular alkalinization is an early event in malignant transformation and plays an essential role in the development of subsequent transformation-associated phenotypes. FASEB J 2000; 14: 2185-97.
12. + antiporter in normal and transformed human lymphocytes and fibroblasts. Am J Physiol 1994; 267: C745-52.
13. + exchange, motility, and invasion induced by serum deprivation. J Biol Chem 2000;275: 5361-9.
14. Pouyssegur J, Franchi A, Pages G. pHi, aerobic glycolysis and vascular endothelial growth factor in tumor growth. Novartis Found Symp 2001; 240: 186-96.
15. + exchanger in metastasis. Nat Rev Cancer 2005; 5: 786-95.
16. Sonveaux P, Végran F, Schroeder T, et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest. 2008; 118: 3930-42.
17. Newell K, Franchi A, Pouyssegur J, Tannock I. Studies with glyco-lysis-deficient cells suggest that production of lactic acid is not the only cause of tumor acidity. Proc Natl Acad Sci USA 1993; 90: 1127-31.
18. Yamagata M, Hasuda K, Stamato T, Tannock IF. The contribution of lactic acid to acidification of tumors: studies of variant cells lacking lactate dehydrogenase. Br J Cancer 1998; 77: 1726-31.
19. Svastová E, Hulková A, Rafajová M, et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Letters 2004; 577: 439-45
20. Dubois L, Lieuwes NG, Maresca A, et al. Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumor model. Radiother. Oncol. 2009; 92: 423-8.
21. Kivelä AJ, Parkkila S, Saarnio J, et al. Expression of the membrane-associated carbonic anhydrase isozyme XII in the human kidney and renal tumors. Histochem Cell Biol 2000; 114: 197-204.
22. Swietach P, Wigfield S, Cobden P, Supuran CT, Harris AL, Vaughan-Jones RD. Tumor-associated carbonic anhydrase 9 spatially coordinates intracellular pH in three-dimensional multicellular growth. J Biol Chem 2008; 283: 20473-83.
23. Ahlskog JKJ, Dumelin CE, Trüssel S, Marlind J, Neri D. In vivo targeting of tumor-associated carbonic anhydrases using acetazo-lamide derivatives. Bioorg Med Chem Lett 2009; 19, 4851-6.
24. Lou Y, McDonald PC, Oloumi A, et al. Targeting Tumor Hypoxia: Suppression of Breast Tumor Growth and Metastasis by Novel Carbonic Anhydrase IX Inhibitors. Cancer Res. 2011; 71: 3364-76
25. Pacchiano F, Carta F, McDonald PC, et al. Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J Med Chem 2011; 54: 1896-902.
26. Zatovicova M, Jelenska L, Hulikova A, et al. Carbonic anhydrase IX as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain. Curr Pharm Des. 2010; 16: 3255-63.
27. Gillies RJ, Raghunand N, Karczmar GS, Bhujwalla ZM. MRI of the tumor microenvironment. J Magn Reson Imaging 2002; 16: 430-450.
28. Raghunand N, Gillies RJ. pH and drug resistance in tumors. Drug Resist Updat 2000; 3: 39-47.
29. Morita T, Nagaki T, Fukuda I, Okumura K. Clastogenicity of low pH to various cultured mammalian cells. Mutat Res 1992; 268: 297-305.
30. Glunde K, Guggino SE, Solaiyappan M, Pathak AP, Ichikawa Y, Bhujwalla ZM. Extracellular acidification alters lysosomal trafficking in human breast cancer cells. Neoplasia 2003; 5: 533-45.
31. Condeelis J, Segall JE. Intravital imaging of cell movement in tumors. Nat Rev Cancer 2003; 3: 921-30.
32. Rofstad EK, Mathiesen B, Kindem K, Galappathi K. Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. Cancer Res 2006; 66: 6699-707.
33. Martinez-Zaguilan R, Seftor EA, Seftor RE, Chu YW, Gillies RJ, Hendrix MJ. Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis 1996; 14: 176-186.
34. Sennoune SR, Martinez-Zaguilan R. Plasmalemmal vacuolar H+-ATPases in angiogenesis, diabetes and cancer. J Bioenerg Biomembr 2007; 39: 427-33.
35. Perez-Sayans M, Reboiras-Lopez MD, Somoza-Martin JM, Barros-Angueira F, Gayoso Diz P, Gandara Rey JM, et al. Measurement of ATP6V1C1 expression in brush cytology samples as a diagnostic and prognostic marker in oral squamous cell carcinoma. Cancer Biol Ther 2010; 25; 9.
36. Kato Y, Lambert CA, Colige AC, et al. Acidic extracellular pH induces matrix metalloproteinase-9 expression in mouse metastatic melanoma cells through the phospholipase D-mitogen-activated protein kinase signaling. J Biol Chem 2005; 280: 10938-44.
37. Johnson LL, Pavlovsky AG, Johnson AR, et al. A rationalization of the acidic pH dependence for stromelysin-1 (Matrix metalloprote-inase-3) catalysis and inhibition. J Biol Chem 2000; 275: 11026-33.
38. Perez-Sayans M, Somoza-Martin JM, Barros-Angueira F, Rey JM, Garcia-Garcia A. V-ATPase inhibitors and implication in cancer treatment. Cancer Treat Rev 2009; 35: 707-13.
39. Fais S. Proton pump inhibitor-induced tumor cell death by inhibition of a detoxification mechanism. J Intern Med 2010; 267; 515-25.
40. Spugnini E, Citro G, Fais S. Proton pump inhibitors as anti vacuo-lar-ATPases drugs: a novel anticancer strategy. J Exp Clin Cancer Res 2010; 29: 44.
41. Griffiths JR. Are cancer cells acidic? Br J Cancer 1991; 64: 425-7.
42. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed 1992; 5: 303-24.
43. De Milito A, Fais S. Proton pump inhibitors may reduce tumor resistance. Expert Opin Pharmacother 2005; 6: 1049-54.
44. De Milito A, Fais S. Tumor acidity, chemoresistance and proton pump inhibitors. Future Oncol 2005; 1: 779-786.
45. Luciani F, Spada M, De Milito A, et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst 2004; 96: 1702-13.
46. Bowman EJ, Siebers A, Altendorf K. Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells. Proc Natl Acad Sci USA 1988; 85: 7972-6.
47. Bowman EJ, Graham LA, Stevens TH, Bowman BJ. The bafilomy-cin/concanamycin binding site in subunit c of the V-ATPases from Neurospora crassa and Saccharomyces cerevisiae. J Biol Chem 2004; 279: 33131-8.
48. Lim JH, Park JW, Kim MS, Park SK, Johnson RS, Chun YS. Bafilomycin induces the p21-mediated growth inhibition of cancer cells under hypoxic conditions by expressing
49. Sennoune SR, Bakunts K, Martinez GM, et al. Vacuolar H+-ATPase in human breast cancer cells with distinct metastatic potential: distribution and functional activity. Am J Physiol Cell Physiol 2004; 286: C1443-52.
50. Perez-Sayans M, Garcia-Garcia A, Reboiras-Lopez MD, Gandara-Vila P. Role of V-ATPases in solid tumors: Importance of the subunit C (Review). Int J Oncol 2009; 34: 1513-20.
51. Horn, J. The proton-pump inhibitors: Similarities and differences. Clin Ther 2000; 22; 266-80.
52. Fais S, De Milito A, You H, Qin W. Targeting vacuolar H+-ATPases as a new strategy against cancer. Cancer Res 2007; 67: 10627-30.
53. De Milito A, Iessi E, Logozzi M, et al. Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species. Cancer Res 2007; 67: 5408-17.
54. Tanigawara Y. Role of P-glycoprotein in drug disposition. Ther Drug Monit 2000; 22: 137-40.
55. McLeod HL, Evans WE. Oral cancer chemotherapy: the promise and the pitfalls. Clin Cancer Res 1999; 5: 2669-71.
56. Perez-Sayans M, Somoza-Martin JM, Barros-Angueira F, Diz PG, Rey JM, Garcia-Garcia A. Multidrug resistance in oral squamous cell carcinoma: The role of vacuolar ATPases. Cancer Lett 2010; 295: 135-43.
57. Aiko K, Tsujisawa T, Koseki T, et al. Involvement of cytochrome c and caspases in apoptotic cell death of human submandibular gland ductal cells induced by concanamycin A. Cell Signal 2002; 14: 717-22.
58. Wu YC, Wu WK, Li Y, et al. Inhibition of macroautophagy by bafilomycin A1 lowers proliferation and induces apoptosis in colon cancer cells. Biochem Biophys Res Commun 2009; 382: 451-6.
59. Alterio V, Hilvo M, Di Fiore A, et al. Crystal structure of the extracellular catalytic domain of the tumor-associated human carbonic anhydrase IX. Proc Natl Acad Sci USA 2009; 106: 16233-8.
60. Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev 2003; 23: 146-89.
61. Supuran CT. Carbonic anhydrase inhibition/activation: Trip of a scientists around the world in the search of novel chemotypes and drug targets. Curr Pharm Des 2010; 16: 3231-2.
62. Supuran CT, Scozzafava A. Carbonic anhydrases as targets for medicinal chemistry. Bioorg Med Chem 2007; 15: 4336-50.
63. Winum JY, Casini A, Mincione F, et al. Carbonic anhydrase inhibitors: N-(p-sulfamoylphenyl)-alpha-D-glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits. Bioorg Med Chem Lett 2004; 14: 225-9.
64. Wilkinson BL, Bornaghi LF, Houston TA, Innocenti A, Supuran CT, Poulsen SA, Novel Class of Carbonic Anhydrase Inhibitors: Glycoconjugate Benzene Sulfonamides Prepared by "Click-Tailing". J Med Chem 2006; 49: 6539-48.
65. Wilkinson BL, Bornaghi LF, Houston TA, et al. Carbonic Anhy-drase Inhibitors: Inhibition of Isozymes I, II and IX with Triazole-linked O-Glycosides of Benzene Sulfonamides. J Med Chem 2007; 60: 1651-57.
66. Wilkinson BL, Innocenti A, Vullo D, Supuran CT, Poulsen SA. Inhibition of Carbonic Anhydrase with Glycosyltriazole Benzene Sulfonamides. J Med Chem 2008; 51: 1945-53.
67. Lopez M, Bornaghi LF, Innocenti A, et al. Sulfonamide Linked Neoglycoconjugates - A New Class of Inhibitors for Cancer-Associated Carbonic Anhydrases. J Med Chem 2010; 53: 2913-26.
68. Colinas PA, Bravo RD, Vullo D, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of cytosolic isoforms I and II, and extracellular isoforms IV, IX and XII with sulfamides incorporating sugar moieties. Bioorg Med Chem Lett 2007; 17: 5086-90.
69. Winum JY, Poulsen SA, Supuran CT. Therapeutic applications of glycosidic carbonic anhydrase inhibitors. Med Res Rev 2009; 29: 419-35.
70. Lopez M, Paul B, Hofmann A, et al. S-Glycosyl Primary Sulfona-mides - A New Structural Class for Selective Inhibition of Cancer-Associated Carbonic Anhydrases. J Med Chem 2009; 52: 6421-32.
71. Winum JY, Temperini C, El Cheikh K, et al. Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue. J Med Chem 2006; 49: 7024-31.
72. Stiti M, Cecchi A, Rami M, et al. Carbonic anhydrase inhibitor coated gold nanoparticles selectively inhibit the tumor-associated isoform IX over the cytosolic ubiquitous isozymes I and II. J Am Chem Soc 2008; 130: 16130-1.
73. Maresca A, Temperini C, Vu H, et al. Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J Am Chem Soc 2009; 131: 3057-62.
74. Maresca A, Temperini C, Pochet L, Masereel B, Scozzafava A, Supuran CT. Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem 2010; 53: 335-44.
75. Maresca A, Supuran CT. Coumarins incorporating hydroxy- and chloro- moieties selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cyto-solic ones I and II. Bioorg Med Chem Lett 2010; 20: 4511-4.
76. Maresca A, Scozzafava A, Supuran CT. 7,8-Disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II in the low nanomolar/subnanomolar range. Bioorg Med Chem Lett 2010; 20: 7255-8.
77. Battke C, Kremmer E, Mysliwietz J, et al. Generation and characterization of the first inhibitory antibody targeting tumor-associated carbonic anhydrase XII. Cancer Immunol Immunother 2011; 60, 649-58.
78. Stillebroer AB, Mulders PF, Boerman OC, Oyen WJ, Oosterwijk E. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol 2010; 58; 75-83.
79. Chrastina A, Závada J, Parkkila S, Kaluz S, et al. Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma. Int J Cancer 2003; 105: 873-81.
80. ®) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol 2011; 29: 121-6.
81. Hoeben BA, Kaanders JH, Franssen GM, et al. PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors. J Nucl Med 2010; 51: 1076-83.
82. Ahlskog JK, Schliemann C, Mårlind J, et al. Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumors. Br J Cancer 2009; 101: 645-57.
83. 99mTc-labeled monoclonal antibody G250 preparations. J Nucl Med 1999; 40: 829-36.
84. van Schaijk FG, Oosterwijk E, Soede AC, et al. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models. J Nucl Med 2005; 46: 495-501.
85. Scozzafava A, Casini A, Supuran CT. Targeting cysteine residues of biomolecules: new approaches for the design of antiviral and anticancer drugs. Curr Med Chem 2002; 9: 1167-85.